Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication

NCT04800692 is registered in ClinicalTrials.gov with Louis Messina as lead sponsor.

NCT NCT04800692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04800692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication
Lead sponsor
Louis Messina
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 15, 2021
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

claudication, intermittent, peripheral artery disease, peripheral vascular diseases